Dance Biopharm, which is developing an insulin soft mist inhaler, has named Melissa Rhodes as Chief Development Officer and Michael Kaseta as its new Chief Financial Officer. The company said that former CFO Don Huffman will continue to act as an advisor. Rhodes was most recently Chief Development Officer at Roivant's Altavant Sciences and was previously Senior VP … [Read more...] about Dance Biopharm appoints new CFO and Chief Development Officer
News
Harro Höfliger announces management changes
Inhaler filling experts Harro Höfliger have announced a number of management changes after the retirement of its founder, Harro Höfliger, who has been succeeded by his son, Markus Höfliger as Chairman of the Supervisory Board. Markus Höfliger was formerly Chief Financial Officer; Turgay Güngormus will now take over as CFO. According to the company, Harro Höfliger … [Read more...] about Harro Höfliger announces management changes
MannKind announces low cost direct purchase program for Afrezza inhaled insulin
MannKind Corporation has announced that it will offer Afrezza inhaled insulin directly to diabetes patients in the US and is also introducing a savings card program for US patients with commercial insurance . The direct purchase program is administered by Eagle Pharmacy. The first 1,000 patients to register for the direct purchase program will be eligible for … [Read more...] about MannKind announces low cost direct purchase program for Afrezza inhaled insulin
StellaPharma acquires dry powder nasal epinephrine formulation
US-based StellaPharma has announced that it will acquire G2B Pharma (G2B) and its dry powder nasal formulation of epinephrine for the treatment of anaphylaxis. According to a 2014 press release, G2B had licensed SNBL's nasal delivery technology and was co-developing G2B011 epinephrine nasal spray with SNBL. Neither StellaPharma nor G2B appears to have a website … [Read more...] about StellaPharma acquires dry powder nasal epinephrine formulation
Nanoform appoints Niklas Sandler as Chief Technology Officer
Nanoform, which recently announced construction of a new GMP manufacturing facility in Helsinki, has announced the appointment of Niklas Sandler as Chief Technology Officer. Sandler was most recently Vice Rector responsible for Research Affairs and Professor of Pharmaceutical Technology at Åbo Akademi University, and he is Chairman of the Board of the Finnish … [Read more...] about Nanoform appoints Niklas Sandler as Chief Technology Officer
Yuhan to commercialize Glenmark’s Ryaltris nasal spray in South Korea
Glenmark Pharmaceuticals will receive an upfront payment, milestones, and royalties from Yuhan Corporation as part of a deal that gives Yuhan rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in South Korea, Glenmark said. Specific terms of the deal were not disclosed. In July … [Read more...] about Yuhan to commercialize Glenmark’s Ryaltris nasal spray in South Korea
Verona Pharma’s RPL554 gets international non-proprietary name “ensifentrine”
According to Verona Pharma, the World Health Organization (WHO) has approved the name “ensifentrine” as the international non-proprietary name for the company’s RPL554 inhaled PDE3/PDE4 inhibitor, which is in development as both an MDI and a DPI for the treatment of respiratory diseases. Verona Pharma CEO Anders Karlsson said, “We are pleased to receive approval … [Read more...] about Verona Pharma’s RPL554 gets international non-proprietary name “ensifentrine”
Insys announces results from PK study of its epinephrine nasal spray
Insys Therapeutics said that a dose finding study of its epinephrine nasal spray that enrolled 49 healthy volunteers demonstrated that one of two doses of the nasal spray tested had a PK profile comparable to the PK profiles of EpiPen (0.3 mg) and Adrenalin (0.5 mg). In June 2018, the company reported results from a proof of concept PK study that showed similar … [Read more...] about Insys announces results from PK study of its epinephrine nasal spray
Evoke Pharma partners with Novus Growth Partners for commercialization of Gimoti nasal spray
Evoke Pharma said that it has signed a deal with Novos Growth Partners (NGP) for commercialization of its Gimoti metoclopramide nasal spray for the treatment of acute and recurrent diabetic gastroparesis in adult women. Evoke's NDA for Gimoti was submitted in June 2018, and the FDA set a PDUFA date of April 1, 2019 for completion of its review. According to Evoke, … [Read more...] about Evoke Pharma partners with Novus Growth Partners for commercialization of Gimoti nasal spray
Verona Pharma names Kathleen Rickard as CMO and Tara Rheault as VP of R&D
Verona Pharma, which is developing an inhaled PDE3/PDE4 inhibitor, has named Kathleen Rickard as Chief Medical Officer and Tara Rheault as VP of Research and Development Operations and Global Project Management. Rickard has previously served as Chief Medical Officer at Aerocrine, Head of Clinical Development at Circassia, and VP Clinical Development and Medical … [Read more...] about Verona Pharma names Kathleen Rickard as CMO and Tara Rheault as VP of R&D